1. Introduction {#sec1-ijms-18-00554}
===============

Resveratrol is a stilbene-based, polyphenolic compound occurring naturally in nuts, berries, and the skin of grapes, and is present in many food items, particularly red wine \[[@B1-ijms-18-00554]\]. In recent years, the clinical effects of resveratrol have been studied intensively owing to a plethora of promising effects in cells and animals; among these are improvement in terms of the various consequences of obesity, e.g., impaired insulin sensitivity and low-grade inflammation \[[@B2-ijms-18-00554],[@B3-ijms-18-00554],[@B4-ijms-18-00554]\]. A landmark study demonstrated a shortened life span in diet-induced obese mice and a resveratrol-mediated improvement in longevity despite obesity \[[@B5-ijms-18-00554]\]. Owing to its purported salutary effects, resveratrol is already being sold as an over-the-counter dietary supplement. Unfortunately, translating the effects of resveratrol to a human setting has proven difficult. Some clinical studies have confirmed the pre-clinical results of resveratrol-mediated improved insulin sensitivity, diminished low-grade inflammation, reduced blood pressure, and reduced amounts of liver fat accumulation \[[@B6-ijms-18-00554],[@B7-ijms-18-00554]\]. In contrast, other studies fail to detect any positive physiological effects \[[@B8-ijms-18-00554],[@B9-ijms-18-00554]\]. These conflicting results may in part be attributable to differences in study designs, populations, and resveratrol formulations. Some studies have been performed in healthy individuals, and the ability of resveratrol to improve glucose handling in situations with normal glucose homoeostasis has been questioned \[[@B8-ijms-18-00554]\]. In contrast, it is feasible that the effect of a food ingredient is too weak to demonstrate any measurable consequences in full-blown type 2 diabetes. Thus, subjects suffering from modest degrees of insulin resistance are most likely optimal for the purpose of investigating the possible effects of resveratrol on insulin sensitivity, and probably most comparable to the original mice studies using diet-induced obese mice. Study length may also be of importance. Most studies include intervention periods of only a few weeks \[[@B6-ijms-18-00554],[@B9-ijms-18-00554]\]. Obviously, longer studies provide a better determination of the possible effects of resveratrol on chronic conditions such as insulin resistance and low-grade inflammation. Finally, the methods currently used in most studies on resveratrol are targeted towards whole-body effects. Insulin sensitivity, for instance, has been assessed via measurements of specific targets such as plasma insulin, glucose, and HbA1c \[[@B6-ijms-18-00554],[@B8-ijms-18-00554],[@B9-ijms-18-00554]\]. These techniques have their strengths, such as being very specific and applicable in daily clinics; however, the drawback is that findings will be limited to the pre-specified objectives. Likewise, when confining assessment to plasma samples, intracellular effects may be missed.

Recently, the so-called metabolomics approach has been developed. Metabolomic analysis profiles small-molecule metabolites using either a targeted or non-targeted approach \[[@B10-ijms-18-00554]\]. Through systematic identification and quantification of metabolites in biological systems, e.g. tissues, organs, or fluids at a certain time point, metabolomics directly sample metabolic modulations. Targeted metabolomics allows for very precise measurement of a specific target or an isolated group of related metabolites, whereas non-targeted metabolomics assesses as wide a range of different metabolites as possible. This technique provides a simultaneous screening of multiple metabolic pathways and captures an instantaneous integrated snapshot of the entire physiology of an organism. Metabolomics has the advantage over other "omics" that it integrates changes in gene expression, protein levels, enzymatic activity, and post-translational changes. Previously, metabolomics made it possible to determine changes in the human plasma metabolome caused by various conditions and diseases like sleep restriction \[[@B11-ijms-18-00554],[@B12-ijms-18-00554]\], diabetes \[[@B13-ijms-18-00554]\], and bariatric surgery \[[@B14-ijms-18-00554]\].

Studies have demonstrated a weak correlation between plasma and muscle metabolite levels, indicating that plasma measurements are poor indicators of skeletal muscle metabolism \[[@B15-ijms-18-00554]\]. Consequently, metabolomic analysis requires tissue biopsies to allow a detailed examination of changes in the intracellular pathways within this specific tissue. Such metabolic profiling offers the possibility to identify biochemical signatures of cellular metabolism involved in different pathways like glucose, lipid, and protein handling.

Massive research interest has gone into resveratrol as a potential protective compound in the management of obesity-associated complications, e.g., metabolic syndrome and low-grade inflammation. However, the particular pathways involved in potential salutary effects are by and large undetermined. Non-targeted metabolomic profiling may provide new insight into these matters. We have recently conducted a four-month randomized, placebo-controlled clinical trial describing the effects of resveratrol treatment in middle-aged males with metabolic syndrome and reported the findings on bone \[[@B16-ijms-18-00554]\], circulating steroids \[[@B17-ijms-18-00554]\], and glucose metabolism and inflammation \[[@B18-ijms-18-00554]\]. The aim of the present study is to provide a comprehensive metabolomic analysis of the changes caused by four months of high-dose resveratrol treatment in these middle-aged men with metabolic syndrome. As the effects of resveratrol in humans are incompletely characterized, we used a non-targeted metabolomics approach based on four different matrices: plasma, urine, adipose tissue, and skeletal muscle tissue from each study subject. In our study on circulating steroids and prostate size we established a dose-dependent decrease in plasma androgen precursors by resveratrol \[[@B17-ijms-18-00554]\]. In order to maximize the chances of detecting even subtle resveratrol-induced pathway changes, we therefore decided to employ the metabolomics analysis in the high-dose resveratrol (hRSV) (500 mg twice daily) group compared to the placebo group.

2. Results {#sec2-ijms-18-00554}
==========

2.1. Clinical Features {#sec2dot1-ijms-18-00554}
----------------------

The basic characteristics of the participants are outlined in [Table 1](#ijms-18-00554-t001){ref-type="table"}. Apart from a slight difference in age, the two groups were comparable at baseline and post-treatment.

2.2. Global Metabolic Profiling {#sec2dot2-ijms-18-00554}
-------------------------------

Based on a combination of two Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS) platforms and one Gas Chromatography--Mass Spectroscopy (GS-MS) platform, 405 metabolites in plasma, 282 metabolites in adipose tissue, 446 metabolites in skeletal muscle, and 604 metabolites in urine were identified. General platform methods, data analysis, and metabolite detection identification are described in detail in the [Supplementary Materials](#app1-ijms-18-00554){ref-type="app"} (see [Supplementary Appendix](#app1-ijms-18-00554){ref-type="app"} and [Supplementary Tables S1--S4](#app1-ijms-18-00554){ref-type="app"}). A total of 88 identified metabolites were present in all four matrices, as illustrated in [Figure 1](#ijms-18-00554-f001){ref-type="fig"}. The relationship between significantly hRSV-changed metabolites in the four matrices is depicted in [Figure 2](#ijms-18-00554-f002){ref-type="fig"}. Adipose tissue and urine had the greatest overlap in terms of significantly changed metabolites. One metabolite, dehydroisoandrosterone sulfate (DHEA-S), was significantly changed in all four matrices.

Random forest analysis (RF analysis) of adipose tissue, muscle tissue, urine, and plasma metabolic profiles resulted in 75%, 87%, 82%, and 89% accuracy in differentiating the hRSV and placebo groups, respectively, indicating that the differences in biochemical profiles between the two groups were quite pronounced. Random Forest classification results, methods, and data analysis are described in detail in the [Supplementary Materials](#app1-ijms-18-00554){ref-type="app"} (see [Supplementary Appendix](#app1-ijms-18-00554){ref-type="app"} and [Supplementary Table S7](#app1-ijms-18-00554){ref-type="app"}). Among the 30 top-ranking metabolites resulting from the RF analysis, biochemicals involved in amino acid metabolism and lipid metabolism were particularly important with regards to the separation of the two groups. Many of the metabolites embraced in the RF-analysis are also included in the hRSV-altered metabolic pathways. Steroid hormones, especially, were well represented in the RF importance plots, in addition to being significantly altered by hRSV intervention.

2.3. Metabolic Profiling in Adipose Tissue {#sec2dot3-ijms-18-00554}
------------------------------------------

Of the 282 biochemicals identified in adipose, tissue 45 displayed a significant change (*p* ≤ 0.05) in response to hRSV treatment: 31 of these were elevated and 14 were reduced. Furthermore, for 28 compounds there was a trend towards a change (*p* \< 0.10), of which 24 compounds were increased and four compounds were reduced by hRSV treatment. The pathways that differed significantly between the hRSV group and controls in adipose tissue (*p* \< 0.05) are shown in [Figure 3](#ijms-18-00554-f003){ref-type="fig"}.

Exploring the respective significantly changed pathways in detail reveals the specific hRSV-affected compounds. As illustrated in [Table 2](#ijms-18-00554-t002){ref-type="table"}, four out of 15 identified lipids are significantly elevated in the long-chain fatty acid pathway (myristate (14:0), myristoleate (14:1n5), palmitate (16:0), and palmitoleate (16:1n7)). These lipids depict the significant fold change between the hRSV group and the placebo group. In addition, examining the polyunsaturated fatty acid pathway demonstrated that six out of 13 identified lipids are significantly elevated in the hRSV group (stearidonate (18:4n3), docosapentaenoate (n3 DPA; 22:5n3), docosahexaenoate (DHA; 22:6n3) linoleate (18:2n6) adrenate (22:4n6), and mead acid (20:3n9)). Also of interest, the steroid hormone pathway reveals significant reductions in both of the identified steroids, dehydroisoandrosterone sulfate (DHEA-S) and 4-androsten-3β, 17β-diol disulfate.

The most interesting trending changes (*p* \< 0.10) in adipose tissue pathways were displayed in the glycolysis, gluconeogenesis, and pyruvate metabolism pathway and the pentose phosphate pathway. As illustrated in [Table 2](#ijms-18-00554-t002){ref-type="table"}, trending elevation in three out of nine identified glycolytic pathway intermediates (glucose-6-phosphate (G6P), dihydroxyacetone phosphate (DHAP), 3-phosphoglycerate, phosphoenolpyruvate (PEP)), and one in the pentose phosphate pathway intermediate was found (sedoheptulose-7-phosphate).

2.4. Metabolic Profiling in Plasma {#sec2dot4-ijms-18-00554}
----------------------------------

Of the 405 named compounds in plasma, 38 were statistically different between the two groups (*p ≤* 0.05); 13 of these were elevated and 25 were reduced. In addition, 11 compounds showed a trend towards a change by hRSV (*p* \< 0.10), of which eight were increased and three were reduced. The pathways that are significantly different (*p* \< 0.05) between the hRSV group and controls are shown in [Figure 4](#ijms-18-00554-f004){ref-type="fig"}.

Particularly interesting changes in response to hRSV treatment were found in the steroid hormone pathway with consistent significant reductions in circulating levels of cholesterol-derived steroid hormones and sulfated steroid hormones. As illustrated in [Table 3](#ijms-18-00554-t003){ref-type="table"}, 13 out of 19 detected steroid hormones were significantly reduced.

Also noteworthy, significant elevations in histidine and the related biochemical marker of muscle protein turnover 3-methylhistidine along with its acetylated derivative *N*-acetyl-3-methylhistidine were observed in plasma in response to hRSV treatment. In addition, subtle but consistent reductions in the dicarboxylic acids dodecanedioate, tetradecanedioate, sebacate, hexadecanedioate, and octadecanedioate were observed in the hRSV group.

2.5. Metabolic Profiling in Skeletal Muscle Tissue {#sec2dot5-ijms-18-00554}
--------------------------------------------------

Of the 446 named biochemicals in skeletal muscle tissue, 24 changed significantly (*p* ≤ 0.05); 12 of these were elevated and 12 reduced by hRSV treatment. Additionally, 19 biochemicals showed a trend towards a change by hRSV (*p* \< 0.10), with 12 biochemicals increased and seven reduced. The pathways that are significantly different (*p* \< 0.05) between the hRSV group and controls are shown in [Figure 5](#ijms-18-00554-f005){ref-type="fig"}.

The most striking change in muscle tissue was the effect of hRSV on the steroid hormone pathway, with four out of six compounds being significantly reduced, as illustrated in [Table 4](#ijms-18-00554-t004){ref-type="table"}. All four compounds comprised sulfated steroid metabolites (dehydroisoandrosterone sulfate (DHEA-S), epiandrosterone sulfate, androsterone sulfate, 4-androsten-3β, and 17β-diol disulfate 1).

Regarding skeletal muscle lipid metabolism, our analysis revealed significant hRSV alterations in the short-chain fatty acids, medium-chain fatty acid, and long-chain fatty acid pathways. Generally, the hRSV group had lower levels of intracellular lipids. In addition, two out of 12 biochemicals in the polyunsaturated fatty acid pathway were increased (stearidonate (18:4n3) and linolenate \[α or γ; (18:3n3 or 6)\]).

2.6. Metabolic Profiling in Urine {#sec2dot6-ijms-18-00554}
---------------------------------

Urine data were analyzed in both non-normalized and osmolality-normalized formats, and because normalization to osmolality values did not substantially affect results, non-normalized data were utilized for data interpretation. Of the 604 named biochemicals in urine, 43 changed significantly (*p* ≤ 0.05); 31 of these were elevated and 12 were reduced by hRSV treatment. Additionally, 27 biochemicals showed a trend towards a change by hRSV (*p* \< 0.10), with 22 biochemicals increased and five reduced. Pathways that demonstrated significantly modifications (*p* \< 0.05) in response to hRSV are shown in [Figure 6](#ijms-18-00554-f006){ref-type="fig"}.

The most striking hRSV-induced changes in urine were observed in the steroid hormone pathway. Ten out of 28 named steroids were significantly changed, with the majority being elevated, as illustrated in [Table 5](#ijms-18-00554-t005){ref-type="table"}.

Furthermore, several metabolites derived from aromatic amino acids that have a contribution from or are exclusively produced by the gut microbiota were altered in the urine. The tyrosine-derived metabolites tyramine, phenol sulfate and homovanillate (HVA), were changed in the hRSV group. Similarly, urinary levels of derivatives from the tryptophan metabolism (tryptamine and indolelactate), the phenyalanine metabolism (2-hydroxyphenylacetate), and the histidine metabolism (imidazole propionate) were significantly altered by hRSV treatment, as depicted in [Table 5](#ijms-18-00554-t005){ref-type="table"}.

3. Discussion {#sec3-ijms-18-00554}
=============

The effects of resveratrol in human trials have proven to be very inconsistent. Most data represent standard biochemical analyses of selected parameters. The focus has been on inflammation \[[@B8-ijms-18-00554],[@B19-ijms-18-00554]\], glucose metabolism \[[@B9-ijms-18-00554],[@B20-ijms-18-00554]\], lipids \[[@B21-ijms-18-00554]\], liver function \[[@B22-ijms-18-00554]\], and steroids \[[@B17-ijms-18-00554]\], assessed by measurement in blood samples, thus representing a picture of whole body metabolism. The present paper describes an exhaustive metabolomic profile of blood, adipose tissue, skeletal muscle tissue, and urine from a comprehensive clinical trial of high-dose resveratrol-treated, middle-aged males with metabolic syndrome. This approach allows for a more elaborate investigation of subtle resveratrol effects on distinct intracellular pathways than what is possible by measurements confined to blood. In addition, this approach of unbiased measurements in various body compartments may help us to determine the cause of some of the effects we have previously detected. Recently, we reported that the androgen precursors in blood were significantly reduced after resveratrol treatment for four months \[[@B17-ijms-18-00554]\]. The presented metabolomic analysis was performed in the same study cohort, and by using this advanced technique we are able to verify the decrease in sulfated androgen precursors in the blood \[[@B17-ijms-18-00554]\]. In addition, we find significantly lower intracellular amounts of sulfated androgen precursors in skeletal muscle tissue as well as adipose tissue. Sulfation is a common modification to control levels of active steroid hormones at target sites by increasing solubility and renal excretion. The metabolomic profiling of urine revealed increased urinary excretion of the majority of the measured sulfated steroid hormones. In the original paper on reduced androgen precursors, we discussed whether the reduction was caused by decreased formation or increased excretion. The present results propose that at least part of the decrease in sulfated androgen precursors in blood and tissues is caused by an increase in urinary excretion of the sulfated steroids.

The metabolomic analysis of lipids points to a striking accumulation of long-chain saturated, monounsaturated, and polyunsaturated (n3 and n6) free fatty acids in adipose tissue. However, in skeletal muscle two long-chain lipids were significantly changed; one was elevated (10-heptadecenoate (17:1n7)) whereas the other was significantly reduced (arachidate (20:0)). Deducing how resveratrol induces the increase in many of the long-chain polyunsaturated fatty acids (n3 and n6) in adipose tissue is complex. Usually these long-chain polyunsaturated fatty acids derive from increased intake of seafood or special plant oils. However, the two essential fatty acids alpha-linolenic acid (ALA; 18:3n3) and linoleic acid (LA; 18:2n6) can be metabolized into longer-chain polyunsaturated fatty acids through a series of desaturation and elongation processes \[[@B23-ijms-18-00554]\]. The literature describes a gender difference in the conversion of ALA to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with women having a much higher conversion rate than men \[[@B24-ijms-18-00554],[@B25-ijms-18-00554]\]. This difference depends upon sex steroids, and testosterone supplementation to female transsexuals reduced DHA concentration by 22% \[[@B26-ijms-18-00554]\]. Clearly, this indicates that the enzymes responsible for the desaturation and elongation conversion of ALA to DHA are negatively regulated by androgens. Based on this knowledge, we speculate that resveratrol might stimulate the conversion process of ALA and LA, resulting in an increase in long-chain polyunsaturated fatty acids through the robust reduction in androgen precursors.

The health impacts of changes in levels of long-chain polyunsaturated fatty acids are still not fully determined. Long-chain polyunsaturated fatty acids have been associated with a positive effect on insulin signaling via the insulin receptor \[[@B27-ijms-18-00554]\], and even a minor increase of ALA content in adipose tissue of 1% has been associated with a 5 mmHg decrease in blood pressure \[[@B28-ijms-18-00554]\]. However, intervention studies providing ALA have yielded conflicting results on blood pressure, cholesterol levels, and triglyceride levels, as reviewed by Baker et al. \[[@B23-ijms-18-00554]\]. Also, despite the increase in these fatty acids in adipose tissue after resveratrol treatment, no clinically relevant improvements in blood pressure or insulin sensitivity were observed in our study population \[[@B18-ijms-18-00554]\].

In the adipose tissue we also detected a significant increase in intracellular glycerol and free fatty acids in the resveratrol-treated subjects. In support of this notion, previously published cell culture studies revealed a resveratrol-mediated enhancement of adrenergic stimulated lipolysis in fat cells \[[@B29-ijms-18-00554],[@B30-ijms-18-00554]\].

Moreover, resveratrol treatment caused consistent reductions in several dicarboxylic fatty acids in plasma. These lipids can be produced from peroxisomal-mediated degradation of very long chain fatty acids (\>22 carbons) and subsequently be metabolized via beta-oxidation. Collectively, a decrease in the dicarboxylic fatty acids in plasma could be a result of increased beta-oxidation in adipose tissue.

Regarding glucose metabolism, we found trends toward elevation in glycolytic intermediates and the pentose phosphate pathway (PPP) intermediates (*p* \< 0.10) in adipose tissue in response to resveratrol. Stimulation of the PPP pathway is associated with increased insulin resistance, increased NADPH production, and thus, increased production of free fatty acids \[[@B31-ijms-18-00554]\]. Hence, our metabolomics findings may indicate increased glucose availability and utilization through glycolysis and the pentose phosphate pathway, owing to decreased insulin sensitivity in the males receiving resveratrol. Clinical parameters in the same study subjects support this assumption, as resveratrol increased fructosamine levels after four months of treatment, indicating poorer insulin sensitivity \[[@B18-ijms-18-00554]\].

In the resveratrol-treated group we demonstrated elevation in metabolites related to metabolism of the amino acid histidine. In particular, histidine was significantly increased in the blood and a trending elevation in the related biochemical marker of the muscle protein turnover 3-methylhistidine along with the acetylated derivative *N*-acetyl-3-methylhistidine was also observed. Increase in 3-methylhistidine, which is a post-translationally modified amino acid derived from the muscle contractile proteins actin and myosin, and *N*-acetyl-3-methylhistidine indicates increased muscle turnover in men treated with resveratrol. This finding ties in well with the study by Olesen et al. \[[@B32-ijms-18-00554]\], in which resveratrol blunted the positive effects of exercise training. In contrast, Scribbans et al. found that resveratrol in addition to exercise had positive effects on muscle metabolism with an increase in mitochondrial capacity \[[@B33-ijms-18-00554]\], while others found no effect in humans \[[@B34-ijms-18-00554]\]. Most rodent studies have found positive effects of resveratrol on muscle function \[[@B5-ijms-18-00554],[@B35-ijms-18-00554],[@B36-ijms-18-00554]\]. Clearly, more clinical studies are needed to determine the exact effects of resveratrol on skeletal muscle function.

Finally, we found urinary changes in several tyrosine-derived, tryptophan-derived, phenylalanine-derived, and histidine-derived metabolites. Tryptophan, histidine, and phenylalanine are classified as essential amino acids, which cannot be synthesized de novo by the body. However, gut bacteria may contribute to their production and degradation \[[@B37-ijms-18-00554]\]. Fermentation of tyrosine and tryptophan by colonic bacteria is found to produce phenols and indoles, which are excreted in the urine \[[@B38-ijms-18-00554]\]. Also, imidazole propionate is known to be excreted in the urine and direct degradation of urocanate to imidazole propionate by the intestinal flora was demonstrated in an animal study \[[@B39-ijms-18-00554]\]. Changes in microbiota-related urinary metabolites are proposed to be of relevance to human health. For instance hippurate, phenylacetylglutamine, 4-cresylsulfate, and 4-hydroxyphenylpropionate have been related to body weight, blood pressure, and metabolic syndrome \[[@B40-ijms-18-00554]\], while urinary imiadazole propionate, which we found to be elevated by resveratrol, has been related to intestinal dysfunction \[[@B39-ijms-18-00554]\]. Therefore, the changes in urinary amino acids and derivatives revealed by the metabolomic analysis may imply a resveratrol-induced modulation of the gut flora in men with metabolic syndrome. This is in accordance with studies in rodents where resveratrol has been shown to modulate the gut microbiota directly \[[@B41-ijms-18-00554],[@B42-ijms-18-00554],[@B43-ijms-18-00554]\].

The strengths of the present clinical trial are a carefully selected, strong study design and the advanced metabolomics approach. A high dosage of resveratrol in a relatively long-term study was chosen. Participants were selected because they had metabolic syndrome, a condition considered a prime target for resveratrol. Furthermore, the advanced metabolomics technique was applied in an unbiased approach to four different matrices. However, a limitation of our study is the lack of liver tissue samples. The liver is a highly metabolic organ and a number of experimental studies have provided evidence of the hepatic benefits of resveratrol treatment \[[@B44-ijms-18-00554]\]. Metabolomic profiling of liver tissue from the same study subjects would help complete the metabolic puzzle of resveratrol-induced biochemical effects. Also, metabolomic analysis on feces would have provided insight into possible beneficial effects on the gut microbiota. Finally, it must be kept in mind that the present study used a very high dose of resveratrol (1000 mg), which is impossible to reach from natural food items. Resveratrol has a very low bioavailability owing to a rapid metabolism to glucuronide and sulfate conjugates in the liver. However, it is possible that ingestion of food items rich in resveratrol and other polyphenols might inhibit the metabolism or increase the absorption of resveratrol, resulting in a better bioavailability from food items than from purified resveratrol products \[[@B45-ijms-18-00554],[@B46-ijms-18-00554]\].

4. Materials and Methods {#sec4-ijms-18-00554}
========================

4.1. Study Design {#sec4dot1-ijms-18-00554}
-----------------

Data in the present study comprise a subgroup from our original study describing the effects of resveratrol on bone \[[@B16-ijms-18-00554]\]. As we only obtained tissue samples from 24 subjects in the placebo group and 21 in the hRSV group, the sample size is lower compared to the original paper. The protocol was approved by the Regional Committee on Health Research Ethics (M-20110111) (24 May 2011) and the Danish Data Protection Agency, and the study was conducted in agreement with the Declaration of Helsinki II. Participants were given oral and written information about the purpose and nature of all procedures before informed consent was obtained. The protocol was registered at clinicaltrials.gov (NCT01412645).

The study was a randomized, placebo-controlled, double-blinded, single-center study. Male test subjects with metabolic syndrome (MetS) were randomized to treatment for four months with tablets containing a placebo, low-dose resveratrol (75 mg twice daily), or high-dose resveratrol (500 mg twice daily). The study comprised 66 test subjects. Inclusion criteria were: Male gender, age between 30 and 60 years, and MetS. MetS was defined according to the International Diabetes Federation \[[@B47-ijms-18-00554]\] as central obesity (Waist circumference ≥94 cm and/or BMI \> 30 kg/m^2^) plus any two of the following: raised triglycerides (≥1.7 mmol/L), reduced high-density lipoprotein (HDL) (≤1.03 mmol/L), raised blood pressure (systolic ≥130 mmHg or diastolic ≥85 mmHg), raised fasting plasma glucose (≥5.6 mmol/L), or drug treatment for the individual features. The trial was performed under conditions of weight stability, unchanged diet, unchanged dietary supplements, and strict compliance with the study drug. Metabolomics results from the high-dose resveratrol (1000 mg daily) and the placebo groups after four months' treatment are reported in the present study.

4.2. Samples {#sec4dot2-ijms-18-00554}
------------

Blood and urine samples were collected between 7:30 and 11:00 a.m. after an overnight fast. Biopsy of the abdominal subcutaneous adipose tissue depot was obtained using a liposuction cannula and skeletal muscle biopsy was harvested from the musculus vastus lateralis using a Bergström cannula. All procedures were performed under sterile conditions. Before both biopsies were performed, the area was anesthetized using 5 to 10 mL lidocaine.

4.3. Metabolomic Analysis {#sec4dot3-ijms-18-00554}
-------------------------

Urine, blood, adipose tissue, and skeletal muscle tissue samples were shipped to Metabolon, Inc.^®^, (Durham, NC, USA) on dry ice. Following receipt, samples were stored at −80 °C until analyzed. A recovery standard was added prior to the first step in preparation for quality control (QC). To remove protein, dissociate small molecules bound to protein or trapped in the protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for two minutes followed by centrifugation. The resulting extracts were divided into five fractions: one for analysis by Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS) with positive ion mode electrospray ionization, one for analysis by UPLC-MS/MS with negative ion mode electrospray ionization, one for LC polar platform, one for analysis by Gas Chromatography-Mass Spectroscopy (GC-MS), and one sample was reserved for backup. Raw data were extracted, peak-identified, and processed using Metabolon's hardware and software. More than 3300 commercially available purified standard compounds were used for the identification of compounds in the samples. General platform methods and metabolite detection identification are described in detail in the [Supplementary Materials](#app1-ijms-18-00554){ref-type="app"} (see [Supplementary Appendix](#app1-ijms-18-00554){ref-type="app"}, [Tables S8 and S9](#app1-ijms-18-00554){ref-type="app"}, [Figures S1 and S2](#app1-ijms-18-00554){ref-type="app"}, and [Supplementary Tables S1--S4](#app1-ijms-18-00554){ref-type="app"}).

4.4. Statistical Analysis {#sec4dot4-ijms-18-00554}
-------------------------

Baseline comparisons of the study population were evaluated by unpaired Student's *t*-test after being checked for normality and equal variance using SPSS Statistics version 20 software. Results are expressed as mean ± SEM. The level of significance was 0.05.

The pathway enrichment value (PEV) used in [Figure 3](#ijms-18-00554-f003){ref-type="fig"}, [Figure 4](#ijms-18-00554-f004){ref-type="fig"}, [Figure 5](#ijms-18-00554-f005){ref-type="fig"} and [Figure 6](#ijms-18-00554-f006){ref-type="fig"} is calculated based on the following equation:

A PEV greater than one indicates that the pathway holds more hRSV-regulated compounds relative to the study overall, suggesting that the pathway may be a target of interest in the intervention effects.

In the metabolomic analysis Welch's two-sample *t*-test was used to identify biochemicals that differed significantly between treatment groups, following log transformation and, if necessary, imputation of missing values with the minimum observed value for each compound. *p*-Values ≤ 0.05 were considered statistically significant and values approaching significance (*p* \< 0.10) were reported as well. An estimate of the false discovery rate (*q*-value method) was calculated to take into account the multiple comparisons that normally occur in metabolomics-based studies. Metabolomics statistical methods are described in details in the [Supplementary Materials](#app1-ijms-18-00554){ref-type="app"} (see [Supplementary Appendix](#app1-ijms-18-00554){ref-type="app"} and [Table S10](#app1-ijms-18-00554){ref-type="app"}).

5. Conclusions {#sec5-ijms-18-00554}
==============

Our comprehensive metabolomic analysis revealed small but robust changes in response to high-dose resveratrol treatment. The main finding is that resveratrol lowered sulfated androgen precursors in blood, adipose tissue, and muscle tissue and concurrently increased the content in urine, indicating increased urinary excretion of these sulfated steroids. Furthermore, the content of long-chain polyunsaturated fatty acids in adipose tissue was increased, probably by increased conversion of ALA and LA mediated through reduced androgen precursors. Several metabolites derived from aromatic amino acids associated with the gut microbiota changed, suggesting that resveratrol may affect either the composition or the metabolism of the gut flora. Considering the increasingly recognized role of the gut microbiota in human health and disease, this effect on gut flora activity may represent a potential and import mode of action of resveratrol. Lastly, our results indicate that non-targeted metabolomics is able to broaden our understanding of the many intra-cellular processes regulated by resveratrol treatment. Yet, our study also demonstrates that it is difficult to conclude solely from a single matric, since only a minor overlap between the four matrices we examined was found. Based on this, we suggest that metabolomics are performed in the tissue of interest. Future clinical studies on resveratrol should focus on the steroid metabolism pathway and the direct impact on human gut microbiota, preferably including liver tissue and feces samples.
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![Resveratrol-mediated changes in adipose tissue, expressed as Pathway enrichment values (PEV). Values are based on the significant resveratrol-regulated compounds relative to all detected compounds in the pathway. PEV = (number of significant metabolites in pathway/total number of detected metabolites in pathway)/(total number of significant metabolites/total number of detected metabolites); hRSV: high-dose resveratrol; Ctrl: Placebo group.](ijms-18-00554-g003){#ijms-18-00554-f003}
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![Resveratrol-mediated changes in skeletal muscle tissue expressed as Pathway enrichment values (PEV). Values are based on the significant resveratrol-regulated compounds relative to all detected compounds in the pathway. PEV = (number of significant metabolites in pathway/total number of detected metabolites in pathway)/(total number of significant metabolites/total number of detected metabolites); hRSV: high-dose resveratrol; Ctrl: Placebo group.](ijms-18-00554-g005){#ijms-18-00554-f005}

![Resveratrol-mediated changes in urine expressed as Pathway enrichment values (PEV). Values are based on the significant resveratrol-regulated compounds relative to all detected compounds in the pathway. PEV = (number of significant metabolites in pathway/total number of detected metabolites in pathway)/(total number of significant metabolites/total number of detected metabolites); hRSV: high-dose resveratrol; Ctrl: Placebo group.](ijms-18-00554-g006){#ijms-18-00554-f006}
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###### 

Clinical features at baseline and post-treatment.

  Characteristic                   Placebo (*n* = 24)   hRSV (*n* = 21)   *p*-Value                 
  -------------------------------- -------------------- ----------------- ------------ ------------ -------------
  Age, years                       47.8 ± 1.3                             51.9 ± 1.3                *p* \< 0.05
  Body mass index, kg/m^2^         34.1 ± 0.8           33.4 ± 0.2        33.8 ± 0.7   33.7 ± 0.2   NS
  HOMA-IR                          4.36 ± 0.5           4.19 ± 0.3        3.87 ± 0.5   4.50 ± 0.3   NS
  Systolic blood pressure, mmHg    150 ± 3              142 ± 3           146 ± 2      140 ± 3      NS
  Diastolic blood pressure, mmHg   91.3 ± 2.1           86.0 ± 1.3        89.3 ± 1.7   87.8 ± 1.4   NS

^1^ Data are expressed as mean ± SEM. NS = no significant difference. Comparisons between groups were evaluated by unpaired Student's *t*-test. The level of significance was 0.05.
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###### 

Summary of resveratrol-induced changes in adipose tissue. Identified metabolites in the long-chain fatty acid, polyunsaturated fatty acid (n3 and n6), steroids, glycolysis, gluconeogenesis, and pyruvate metabolism, and pentose phosphate pathways in adipose tissue. Red: Significant elevation (*p* ≤ 0.05). Orange: Trending elevation (*p* \< 0.10); Green: Significant reduction (*p* ≤ 0.05).

  Superpathway                                                                                     Sub Pathway                                                    Biochemical Name               [hRSV]{.ul} Ctrl   *p*-Value   *q*-Value
  ------------------------------------------------------------------------------------------------ -------------------------------------------------------------- ------------------------------ ------------------ ----------- -----------
  **Lipid**                                                                                        Long-Chain Fatty Acid                                          Myristate (14:0)               1.10               0.003       0.111
  Myristoleate (14:1n5)                                                                            1.67                                                           0.017                          0.182                          
  Pentadecanoate (15:0)                                                                            1.01                                                           0.977                          0.816                          
  Palmitate (16:0)                                                                                 1.10                                                           0.033                          0.240                          
  Palmitoleate (16:1n7)                                                                            1.41                                                           0.003                          0.109                          
  Margarate (17:0)                                                                                 0.98                                                           0.500                          0.672                          
  10-heptadecenoate (17:1n7)                                                                       1.12                                                           0.086                          0.309                          
  Stearate (18:0)                                                                                  1.02                                                           0.610                          0.731                          
  Oleate (18:1n9)                                                                                  1.17                                                           0.109                          0.328                          
  *cis*-vaccenate (18:1n7)                                                                         1.17                                                           0.304                          0.538                          
  Nonadecanoate (19:0)                                                                             1.00                                                           0.866                          0.794                          
  10-nonadecenoate (19:1n9)                                                                        1.08                                                           0.569                          0.703                          
  Arachidate (20:0)                                                                                0.94                                                           0.472                          0.660                          
  Eicosenoate (20:1n9 or 11)                                                                       1.12                                                           0.335                          0.566                          
  Erucate (22:1n9)                                                                                 0.96                                                           0.657                          0.734                          
  Polyunsaturated Fatty Acid (n3 and n6)                                                           Stearidonate (18:4n3)                                          1.50                           0.045              0.240       
  Eicosapentaenoate (EPA; 20:5n3)                                                                  1.25                                                           0.093                          0.311                          
  Docosapentaenoate (n3 DPA; 22:5n3)                                                               1.31                                                           0.012                          0.177                          
  Docosahexaenoate (DHA; 22:6n3)                                                                   1.38                                                           0.042                          0.240                          
  Linoleate (18:2n6)                                                                               1.24                                                           0.021                          0.203                          
  Linolenate \[α or γ; (18:3n3 or 6)\]                                                             1.21                                                           0.060                          0.253                          
  Dihomo-linolenate (20:3n3 or n6)                                                                 1.19                                                           0.065                          0.261                          
  Arachidonate (20:4n6)                                                                            1.17                                                           0.107                          0.328                          
  Adrenate (22:4n6)                                                                                1.69                                                           0.010                          0.177                          
  Docosapentaenoate (n6 DPA; 22:5n6)                                                               1.63                                                           0.056                          0.253                          
  Docosadienoate (22:2n6)                                                                          1.10                                                           0.275                          0.498                          
  Dihomo-linoleate (20:2n6)                                                                        1.11                                                           0.216                          0.443                          
  Mead acid (20:3n9)                                                                               1.33                                                           0.045                          0.240                          
  Steroid                                                                                          Dehydroisoandrosterone sulfate (DHEA-S)                        0.40                           0.013              0.177       
  4-androsten-3β,17β-diol disulfate (1)                                                            0.37                                                           0.009                          0.177                          
  **Carbohydrate**                                                                                 Glycolysis, Gluconeogenesis, and pyruvate metabolism pathway   1,5-anhydroglucitol (1,5-AG)   0.86               0.235       0.464
  Glucose                                                                                          0.98                                                           0.594                          0.722                          
  Glucose-6-phosphate (G6P)                                                                        1.23                                                           0.059                          0.253                          
  Isobar: fructose 1,6-diphosphate, glucose 1,6-diphosphate, myo-inositol 1,4 or 1,3-Diphosphate   1.16                                                           0.159                          0.394                          
  Dihydroxyacetone phosphate (DHAP)                                                                1.30                                                           0.080                          0.303                          
  3-phosphoglycerate                                                                               1.75                                                           0.057                          0.253                          
  Phosphoenolpyruvate (PEP)                                                                        1.39                                                           0.128                          0.357                          
  Lactate                                                                                          1.04                                                           0.396                          0.599                          
  Glycerate                                                                                        1.08                                                           0.771                          0.777                          
  Pentose phosphate pathway                                                                        Sedoheptulose-7-phosphate                                      1.27                           0.051              0.253       
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###### 

Summary of resveratrol-induced changes in plasma. Identified metabolites in the steroid, fatty acid dicarboxylate, and histidine metabolism pathways in plasma. Red: Significant elevation (*p* ≤ 0.05). Orange: Trending elevation (*p* \< 0.10); Green: Significant reduction (*p* ≤ 0.05). Light green: Trending reduction (*p* \< 0.10).

  Superpathway                                           Sub Pathway            Biochemical Name       [hRSV]{.ul} Ctrl   *p*-Value   *q*-Value
  ------------------------------------------------------ ---------------------- ---------------------- ------------------ ----------- -----------
  **Lipid**                                              Steroid                Pregnenolone sulfate   0.63               0.001       0.018
  21-hydroxypregnenolone disulfate                       0.41                   \<0.001                \<0.001                        
  5α-pregnan-3β,20α-diol disulfate                       0.42                   \<0.001                \<0.001                        
  5α-pregnan-3α,20β-diol disulfate 1                     0.93                   0.140                  0.762                          
  Pregnen-diol disulfate                                 0.53                   0.001                  0.015                          
  Pregn steroid monosulfate                              0.72                   0.046                  0.515                          
  Pregnanediol-3-glucuronide                             0.92                   0.644                  0.927                          
  Cortisol                                               0.92                   0.745                  0.941                          
  Cortisone                                              0.93                   0.285                  0.824                          
  Dehydroisoandrosterone sulfate (DHEA-S)                0.57                   \<0.001                0.013                          
  Epiandrosterone sulfate                                0.42                   \<0.001                0.004                          
  Androsterone sulfate                                   0.40                   \<0.001                0.004                          
  4-androsten-3β,17β-diol disulfate 1                    0.51                   \<0.001                0.016                          
  4-androsten-3β,17β-diol disulfate 2                    0.49                   \<0.001                \<0.001                        
  5α-androstan-3β,17α-diol disulfate                     0.37                   \<0.001                0.001                          
  5α-androstan-3α,17β-diol disulfate                     0.71                   0.071                  0.659                          
  5α-androstan-3β,17β-diol disulfate                     0.37                   \<0.001                0.002                          
  Andro steroid monosulfate 2                            0.31                   \<0.001                \<0.001                        
  Estrone 3-sulfate                                      0.87                   0.132                  0.762                          
  Fatty Acid, Dicarboxylate                              2-hydroxyglutarate     0.98                   0.660              0.934       
  Sebacate (decanedioate)                                0.73                   0.101                  0.762                          
  Dodecanedioate                                         0.61                   \<0.001                0.001                          
  Tetradecanedioate                                      0.75                   0.021                  0.278                          
  Hexadecanedioate                                       0.85                   0.206                  0.762                          
  Octadecanedioate                                       0.88                   0.255                  0.811                          
  3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF)   0.95                   0.955                  0.964                          
  **Amino Acid**                                         Histidine Metabolism   Histidine              1.16               0.008       0.147
  3-methylhistidine                                      1.93                   0.056                  0.570                          
  *N*-acetyl-3-methylhistidine                           1.23                   0.084                  0.721                          
  *trans*-urocanate                                      1.38                   0.128                  0.762                          
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###### 

Summary of resveratrol-induced changes in skeletal muscle tissue. Identified metabolites in the steroid, short-chain fatty acid, medium-chain fatty acid, long-chain fatty acid, and polyunsaturated fatty acid (n3 and n6) pathways in skeletal muscle. Red: Significant elevation (*p* ≤ 0.05). Orange: Trending elevation (*p* \< 0.10); Green: Significant reduction (*p* ≤ 0.05).

  Superpathway                              Sub Pathway             Biochemical Name   [hRSV]{.ul} Ctrl   *p*-Value   *q*-Value
  ----------------------------------------- ----------------------- ------------------ ------------------ ----------- -----------
  **Lipid**                                 Steroid                 Cortisol           1.40               0.211       0.962
  Cortisone                                 1.14                    0.778              0.987                          
  Dehydroisoandrosterone sulfate (DHEA-S)   0.48                    \<0.001            0.025                          
  Epiandrosterone sulfate                   0.29                    \<0.001            0.001                          
  Androsterone sulfate                      0.24                    \<0.001            0.001                          
  4-androsten-3β,17β-diol disulfate (1)     0.46                    0.002              0.125                          
  Short-Chain Fatty Acid                    Valerate                0.86               \<0.001            0.026       
  Medium-Chain Fatty Acid                   Caproate (6:0)          1.09               0.442              0.962       
  Heptanoate (7:0)                          0.82                    \<0.001            0.032                          
  Caprylate (8:0)                           1.08                    0.619              0.962                          
  Undecanoate (11:0)                        0.89                    0.002              0.125                          
  Long-Chain Fatty Acid                     Myristoleate (14:1n5)   1.78               0.252              0.962       
  Palmitate (16:0)                          0.98                    0.449              0.962                          
  Margarate (17:0)                          0.95                    0.268              0.962                          
  10-heptadecenoate (17:1n7)                1.09                    0.029              0.655                          
  Stearate (18:0)                           0.97                    0.209              0.962                          
  Oleate (18:1n9)                           1.01                    0.994              0.996                          
  *cis*-vaccenate (18:1n7)                  1.02                    0.904              0.995                          
  10-nonadecenoate (19:1n9)                 0.97                    0.882              0.995                          
  Arachidate (20:0)                         0.84                    0.003              0.168                          
  Eicosenoate (20:1n9 or 11)                1.01                    0.958              0.996                          
  Erucate (22:1n9)                          0.88                    0.193              0.962                          
  Polyunsaturated Fatty Acid (n3 and n6)    Stearidonate (18:4n3)   1.45               0.015              0.474       
  Eicosapentaenoate (EPA; 20:5n3)           0.98                    0.554              0.962                          
  Docosapentaenoate (n3 DPA; 22:5n3)        1.04                    0.511              0.962                          
  Docosahexaenoate (DHA; 22:6n3)            1.07                    0.344              0.962                          
  Linoleate (18:2n6)                        1.02                    0.714              0.980                          
  Linolenate \[α or γ; (18:3n3 or 6)\]      1.16                    0.065              0.962                          
  Dihomo-linolenate (20:3n3 or n6)          1.02                    0.873              0.995                          
  Arachidonate (20:4n6)                     1.00                    0.990              0.996                          
  Docosapentaenoate (n6 DPA; 22:5n6)        0.99                    0.994              0.996                          
  Docosadienoate (22:2n6)                   0.93                    0.680              0.962                          
  Dihomo-linoleate (20:2n6)                 0.83                    0.287              0.962                          
  Mead acid (20:3n9)                        0.93                    0.619              0.962                          
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###### 

Summary of resveratrol-induced changes in urine. Identified metabolites in the steroid, tryptophan metabolism, phenylalanine and tyrosine metabolism, and histidine metabolism pathways in urine. Red: Significant elevation (*p* ≤ 0.05). Orange: Trending elevation (*p* \< 0.10); Green: Significant reduction (*p* ≤ 0.05).

  Superpathway                                           Sub Pathway             Biochemical Name                   [hRSV]{.ul}Ctrl   *p*-Value   *q*-Value
  ------------------------------------------------------ ----------------------- ---------------------------------- ----------------- ----------- -----------
  **Lipid**                                              Steroid                 21-hydroxypregnenolone disulfate   0.50              0.012       0.313
  Pregnen-diol disulfate                                 0.79                    0.421                              0.861                         
  Pregn steroid monosulfate                              2.10                    0.008                              0.281                         
  Pregnanediol-3-glucuronide                             0.87                    0.910                              0.938                         
  Cortisol                                               1.29                    0.734                              0.915                         
  Cortisol glucuronide                                   1.36                    0.600                              0.893                         
  Cortisone                                              1.13                    0.757                              0.915                         
  Tetrahydrocortisone                                    1.54                    0.270                              0.762                         
  Dehydroisoandrosterone sulfate (DHEA-S)                3.95                    \<0.001                            0.001                         
  16a-hydroxy DHEA 3-sulfate                             1.04                    0.201                              0.735                         
  Epiandrosterone                                        0.87                    0.967                              0.938                         
  Epiandrosterone sulfate                                1.43                    0.036                              0.575                         
  Androsterone sulfate                                   1.22                    0.171                              0.724                         
  4-androsten-3β,17β-diol monosulfate (1)                3.75                    \<0.001                            0.001                         
  4-androsten-3β,17β-diol monosulfate (2)                3.50                    0.003                              0.149                         
  4-androsten-3α,17α-diol monosulfate (2)                6.78                    \<0.001                            0.001                         
  4-androsten-3β,17β-diol disulfate (1)                  0.72                    0.804                              0.920                         
  4-androsten-3β,17β-diol disulfate (2)                  0.89                    0.736                              0.915                         
  5α-androstan-3β,17α-diol disulfate                     0.20                    0.002                              0.127                         
  5α-androstan-3β,17β-diol disulfate                     0.68                    0.414                              0.861                         
  Andro steroid monosulfate (1)                          0.45                    0.004                              0.170                         
  Testosterone sulfate                                   3.74                    0.009                              0.281                         
  11-ketoetiocholanolone glucuronide                     0.98                    0.793                              0.920                         
  Etiocholanolone glucuronide                            0.85                    0.766                              0.915                         
  17α-hydroxypregnanolone glucuronide                    1.10                    0.216                              0.747                         
  5β-pregnan-3α,21-diol-11,20-dione 21-Glucosiduronate   1.51                    0.604                              0.893                         
  11-ketoetiocholanolone sulfate                         1.23                    0.957                              0.938                         
  Dehydroepiandrosterone glucuronide                     0.83                    0.585                              0.881                         
  **Amino Acid**                                         Tryptophan Metabolism   Tryptophan                         0.99              0.908       0.938
  *N*-acetyltryptophan                                   1.37                    0.194                              0.726                         
  Tryptamine                                             0.37                    \<0.001                            0.010                         
  Indolelactate                                          1.56                    0.050                              0.613                         
  Indoleacetate                                          0.58                    0.201                              0.735                         
  3-indoxyl sulfate                                      1.39                    0.124                              0.724                         
  Kynurenine                                             1.29                    0.637                              0.905                         
  Kynurenate                                             1.17                    0.325                              0.793                         
  Anthranilate                                           1.16                    0.446                              0.861                         
  3-hydroxykynurenine                                    1.43                    0.480                              0.874                         
  3-hydroxyanthranilate                                  1.59                    0.057                              0.638                         
  Xanthurenate                                           1.23                    0.231                              0.748                         
  Picolinate                                             1.16                    0.180                              0.724                         
  5-hydroxytryptophan                                    1.11                    0.383                              0.848                         
  5-hydroxyindoleacetate                                 1.02                    0.563                              0.881                         
  Serotonin (5HT)                                        1.03                    0.782                              0.920                         
  Indoleacetylglutamine                                  0.64                    0.824                              0.920                         
  Tryptophan betaine                                     1.14                    0.976                              0.940                         
  Indole-3-carboxylic acid                               0.93                    0.696                              0.914                         
  *C*-glycosyltryptophan                                 1.03                    0.693                              0.914                         
  *N*-acetylkynurenine (2)                               2.14                    0.047                              0.613                         
  Phenylalanine and Tyrosine Metabolism                  Phenylalanine           1.11                               0.588             0.881       
  *N*-acetylphenylalanine                                1.31                    0.185                              0.726                         
  Phenyllactate (PLA)                                    1.86                    0.148                              0.724                         
  4-hydroxyphenylacetate                                 1.02                    0.915                              0.938                         
  3-hydroxyphenylacetate                                 1.52                    0.096                              0.724                         
  Phenylacetylglycine                                    1.13                    0.801                              0.920                         
  Phenylacetylglutamine                                  0.97                    0.720                              0.914                         
  Tyrosine                                               1.06                    0.693                              0.914                         
  *N*-acetyltyrosine                                     1.47                    0.051                              0.613                         
  4-hydroxycinnamate                                     1.83                    0.172                              0.724                         
  Tyramine                                               0.60                    0.001                              0.075                         
  m-tyramine                                             0.99                    0.923                              0.938                         
  4-hydroxyphenylpyruvate                                2.23                    0.012                              0.313                         
  3-(4-hydroxyphenyl)lactate                             1.33                    0.280                              0.762                         
  Phenol sulfate                                         1.74                    0.016                              0.365                         
  p-cresol sulfate                                       0.87                    0.465                              0.874                         
  o-cresol sulfate                                       1.41                    0.301                              0.782                         
  Dopamine                                               0.37                    0.998                              0.947                         
  Vanillylmandelate (VMA)                                1.08                    0.392                              0.858                         
  3-methoxytyrosine                                      1.08                    0.967                              0.938                         
  3-methoxytyramine                                      1.07                    0.226                              0.748                         
  3-methoxytyramine sulfate                              0.96                    0.301                              0.782                         
  3,4-dihydroxyphenylacetate                             1.32                    0.107                              0.724                         
  Homovanillate (HVA)                                    1.33                    0.040                              0.583                         
  Homovanillate sulfate                                  0.98                    0.565                              0.881                         
  Gentisate                                              1.37                    0.125                              0.724                         
  Phenylpropionylglycine                                 0.95                    0.946                              0.938                         
  3-\[3-(sulfooxy)phenyl\]propanoic acid                 0.66                    0.602                              0.893                         
  3-(3-hydroxyphenyl)propionate                          1.01                    0.903                              0.938                         
  5-hydroxymethyl-2-furoic acid                          0.77                    0.442                              0.861                         
  2-hydroxyphenylacetate                                 1.31                    0.075                              0.721                         
  Phenylacetylcarnitine                                  0.82                    0.542                              0.881                         
  Dopamine sulfate (1)                                   0.48                    0.963                              0.938                         
  Dopamine sulfate (2)                                   0.46                    0.893                              0.938                         
  p-cresol-glucuronide                                   0.95                    0.704                              0.914                         
  Tyramine *O*-sulfate                                   0.69                    0.202                              0.735                         
  Vanillic alcohol sulfate                               0.91                    0.271                              0.762                         
  4-hydroxycinnamate sulfate                             0.47                    0.240                              0.748                         
  3,4-dihydroxyphenylacetate sulfate                     0.69                    0.548                              0.881                         
  Histidine Metabolism                                   Histidine               1.10                               0.402             0.861       
  *N*-acetylhistidine                                    1.12                    0.152                              0.724                         
  1-methylhistidine                                      1.09                    0.712                              0.914                         
  3-methylhistidine                                      2.02                    0.080                              0.724                         
  *N*-acetyl-3-methylhistidine                           2.10                    0.037                              0.576                         
  *N*-acetyl-1-methylhistidine                           1.07                    0.482                              0.874                         
  Hydantoin-5-propionic acid                             1.01                    0.954                              0.938                         
  *trans*-urocanate                                      1.14                    0.280                              0.762                         
  *cis*-urocanate                                        1.11                    0.632                              0.905                         
  Formiminoglutamate                                     1.03                    0.984                              0.943                         
  Imidazole propionate                                   1.67                    0.010                              0.290                         
  Imidazole lactate                                      1.31                    0.280                              0.762                         
  1-methylimidazoleacetate                               1.13                    0.424                              0.861                         
  4-imidazoleacetate                                     1.16                    0.703                              0.914                         
  *N*-acetylhistamine                                    0.80                    0.554                              0.881                         
